G protein alpha subunit, Heterotrimeric G protein, Guanine nucleotide-binding protein, Signaling transducer
01
Overview
G protein subunit alpha-12 (GNA12) is a member of the G12 subfamily of heterotrimeric G protein alpha subunits that link cell surface G protein-coupled receptors (GPCRs) to intracellular signaling cascades. GNA12 couples GPCRs predominantly to Rho guanine nucleotide exchange factors (RhoGEFs), leading to activation of RhoA and reorganization of the actin cytoskeleton, regulation of cell migration, proliferation, and apoptosis. GNA12 also controls transcriptional programs via effectors such as AP-1 and STAT3, and modulates various signaling pathways including PLC, MAPK, TOR, and Na/H exchange. Aberrant GNA12 signaling is implicated in cancer progression, metabolic disorders, and inflammatory responses due to its broad regulatory functions across a variety of tissues
Other names
Guanine nucleotide-binding protein subunit alpha-12G alpha-12GNA12gepHG1M1NNX3RMPguanine nucleotide-binding protein subunit alpha-12WUGSC:H_GS165O14.2g alpha-12guanine nucleotide binding protein (G protein) alpha 12heterotrimeric guanine nucleotide-binding protein 1M1
02
Mechanism of action
Activation or inhibition of upstream GPCRs that preferentially couple to GNA12 (G protein subunit alpha-12) alters downstream RhoA/RhoGEF pathways, actin cytoskeleton, and gene transcription
03
Biological functions
Signal transductionRegulation of actin cytoskeletonRho GTPase activationRegulation of cell growth and proliferationApoptosisCell migrationRegulation of transcription factors (e.g., AP-1, STAT3, SRF)Regulation of TOR signalingModulation of inflammatory cytokine production
04
Disease associations
Cancer (oncogenesis, metastasis, tumor progression)Cardiovascular diseaseMetabolic diseases (implicated in liver fibrosis, glucose metabolism)InflammationHematologic cancersAtrophic rhinitis
05
Safety considerations
Targeting GNA12-related pathways could impact multiple systems due to its ubiquitous roles in cellular signaling.Potential adverse effects may include altered cell proliferation, impaired immune responses, and disruption of cardiovascular or metabolic regulation, owing to the protein’s involvement in many critical cellular and physiological processes
06
Interacting drugs
No direct small-molecule drugs or biologics are currently approved specifically targeting GNA12 itself; it is, however, modulated indirectly via GPCR ligands such as lysophosphatidic acid (LPA) and thromboxane A2 receptor agonists/antagonists
07
Biomarkers
There is currently no established clinical biomarker directly related to GNA12 expression or activity, but aberrant activation may serve as a potential future biomarker in cancer and metabolic diseases
Beyond the preview
Go deeper on G protein subunit alpha-12 (GNA12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on G protein subunit alpha-12 (GNA12).